Additional Relevant Details The comparative studies assessed the impact of a novel topical gel formulation of 1% minocycline and compared it to an extended release oral minocycline to measure skin and plasma concentrations during four-week treatment periods. Results of a 28-day clinical PK study found no detectable minocycline in skin after two weeks of daily oral treatment with a 1-2 mg/kg dose, but did show minocycline concentrations in the plasma. A separate oral gavage versus BPX-01 minipig study also found minocycline in the plasma for minipigs in the oral group, but no minocycline in the plasma for the topical group. At the same time, the minipig study detected minocycline in the skin of the topical group, but found no minocycline in the skin of the oral group. BPX-01 is fully solubilized, non-oily, easy-to-use, and capable of being delivered to sebum-rich areas where P. acnes reside.